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Dose conformity in thoracic and abdominal ion-beam radiotherapy is degraded by respiratory motion. To improve conformity,
an image-guided respiration-gated system can be used in the treatment room. The purpose of this study was to estimate the organ
doses and effective doses to patients from an image-guided respiration-gated system. Glass dosemeters were inserted into an
adult anthropomorphic phantom and were attached to the surface on the phantom. The phantom was placed on the treatment
couch, and the imaging dose from fluoroscopy was evaluated. In addition to the organ doses, the effective doses were also esti-
mated according to the ICRP Publication 103. The irradiation time is over 3–5 min per beam angle. When image acquisition
conditions were assumed for thoracic treatment, the effective doses and maximal skin doses were 0.48–0.79 mSv and 5.9–9.9
mGy, respectively. The estimated doses can be the base data for considering radiological protection in the radiotherapy.
INTRODUCTION
Active beam scanning radiotherapy has recently been
introduced at several particle therapy centres(1 – 3).
This method can deliver doses to complex tumour
volumes with higher conformity than the passive
beam delivery method. However, dose distribution in
active beam scanning is sensitive to changes in target
position and, in lung tissue, to the range variation
caused by density variation with respiration.
Variation in target position and range variation can
cause the degradation of dose conformity. To improve
the precision of target localisation, a number of treat-
ment centres use a respiratory-gated strategy and four-
dimensional computed tomography (4DCT)-based
treatment planning for thoracic and abdominal treat-
ments. An external marker is generally used for respira-
tory monitoring. Indirect respiratory monitoring can
in the worst case result in inconsistency between the
external respiratory signal and internal organ move-
ment(4). To monitor internal organ movement directly,
in-room fluoroscopic marker-tracking systems have
been utilised(5, 6). Since the implantation of metallic
markers carries a risk of pneumothorax, some groups
have introduced real-time tumour tracking systems
that do not use these markers(7, 8). Markerless tracking
systems require higher contrast resolution than
marker-tracking systems. One method of attaining
high contrast images is to increase the X-ray tube
current and exposure time, but this is of course accom-
panied by increasing dose. Some particle therapy insti-
tutes have used 4DCT-based treatment planning to
improve target coverage(9, 10). The imaging dose of
4DCT is four to six times that of helical computed
tomography (CT)(11, 12). Patients with thoracic or ab-
dominal tumours receive substantial benefit from
image guidance, but at the price of increased radiation
dose. Because the total imaging dose is the accumula-
tion of each imaging dose from image guidance, esti-
mation of each imaging dose would be helpful to
optimise the imaging dose and to inform clinicians
about the total imaging dose for a specific treatment
scenario in image-guided radiotherapy.
A new treatment facility for carbon-ion therapy
was constructed at the authors’ institute in 2011, and
over 700 cancer patients were treated with non-
respiratory-gated irradiation by the end of July
2014(3). A markerless tracking system and 4DCT-
based treatment planning have been introduced for
active beam scanning in the thoracic and abdominal
regions. The total imaging dose is the sum of that from
CT planning (4DCT), that from patient setup (orthog-
onal X-ray flat panel detector images), and that from
the markerless tracking system (fluoroscopy). For
image-guided particle radiotherapy, the imaging doses
from 4DCT and fluoroscopy account for a large pro-
portion of the overall imaging dose(13). Although
Matsuzaki et al. showed the organ and effective doses
from 4DCT(12), the authors are unaware of any
reported estimation of the dose from fluoroscopic
tumour tracking systems. Understanding the addition-
al organ dose due to ionising radiation from image
guidance methods is particularly important when the
planned treatment dose to critical organs is already
close to the tolerance limit.
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There were two purposes to this study: the first was
to estimate the imaging doses from fluoroscopy and
the second was to compare the effective doses from
fluoroscopy to those from other imaging modalities.
These results would be helpful to optimise dose and




The fluoroscopic system used in this study was
designed to provide respiratory gating for radiotherapy.
The system consists of a pair of indirect dynamic flat
panel detectors (DFPDs) (PaxScan 3030þ, Varian
Medical Systems, Palo Alto, CA, USA) installed on
the right and left side of vertical irradiation port (08)
at 35 and 3258, and X-ray tubes (UD150B-40 and
0.4/0.7JG326D-265, Shimadzu Co., Kyoto, Japan)
installed under radiolucent floor panels. The imaging
area is 296` 296 mm (actual image size at room iso-
centre 209` 209 mm). Small collimators are posi-
tioned in front of the X-ray tubes, and 0.9 mm
aluminium and 0.01 mm copper filters are employed
to remove lower energy photons. An antiscatter grid is
not used. The image acquisition frame rate is less than
30 frames per second (fps). The effective energy and
the quality index for 60, 80, 100 and 120 kV were mea-
sured in the treatment room. Quality index was defined
as the effective energy divided by the maximal energy
of X-ray beam. The measurement procedure was as
follows: 12 cc ionisation chamber was set at isocentre
in the treatment room. The half-value layer of alumin-
ium was obtained by increasing the thickness of high
purity aluminium plates in the front of X-ray tube. The
mass attenuation coefficients of aluminium were
obtained by the measured half-value layers. Based on
the mass attenuation coefficients, the X-ray effective
energies were estimated by using the data table of the
National Institute of Standards and Technology(14).
Phantom
An adult anthropomorphic phantom (THRA-1;
Kyoto Kagaku Co., Kyoto, Japan) was used for the
dose measurements. The phantom models a human
body with a height of 164 cm and a weight of 54 kg
and is composed of materials equivalent to soft tissue
(mass density: 1.01 g cm23), lung (0.3 g cm23) and
bone (1.24 g cm23). The phantom was attached two
breast parts and testis part, and effective doses of ref-
erence male and reference female were evaluated.
This phantom consists of 35 slices of 2.5 cm thickness
and contains two types of 179 cylindrical 2-mm and
5-mm holes in which glass dosemeters can be inserted
to each organ position. Bone surface doses were esti-
mated at the same position as bone marrow doses.
Remainder, which is defined in the International
Commission on Radiological Protection Publication
103(15), consists of oral mucosa, extrathoracic tissue,
thymus, heart, kidney, pancreas, spleen, adrenal,
small intestine and uterus. The total skin surface area
of the phantom is 1.6 m2.
Dosimeter
The glass dosemeter system, Dose Ace (Asahi Techno
Glass Co., Haibara, Japan) consists of a silver-acti-
vated phosphate glass dosemeter (GD-352M) and a
readout unit (FDG-1000). The shape of the glass
dosemeter is cylindrical, 1.5 mm in diameter and 12
mm in length. The glass dosemeter has an effective
atomic number of 12.04(16). The response of the glass
dosemeter depends on X-ray energy. Energy depend-
ence is remarkably high at lower soft X-ray energy
regions. Energy dependence can be reduced by insert-
ing the glass dosemeter into a Sn filter measuring 4.3
mm in diameter and 14.5 mm length. Glass dose-
meters were inserted into the holder, which contained
Sn filter inside, then inserted into 5-mm holes in the
adult anthropomorphic phantom. Other glass dose-
meters were directly inserted into 2-mm holes. The
authors obtained two types of calibration factor, with
and without Sn filters. The calibration factors were
determined by comparative calibration with either a
0.6 or 12 cc ionisation chamber in a water-equivalent
slab phantom (Figure 1). A 4-mm-thick aluminium
plate was placed in front of the X-ray tube (YXLON
International X-ray GmbH, Hamburg, Germany) to
equalise the effective energy and the quality index
between calibration and measurement in the treatment
room. The ionisation chambers were calibrated with a
traceable ionisation chamber to the National Standard.
The calibration factors were obtained for the following
five conditions: with Sn filter on the surface of the
phantom; with Sn filter in the phantom; without Sn
filter in the phantom; with Sn filter outside the beam
field and without Sn filter outside the beam field.
Data acquisition
The adult anthropomorphic phantom was placed on
the treatment couch in the supine position. The centre
of the phantom was matched to the isocentre in the
treatment room (Figure 2a). Exposure conditions
were tube voltage of 80 kV, tube current of 50 mA,
exposure time 4 ms per pulse and 15 fps. The dose
measurements were carried out with each tube aimed
at the thoracic and abdominal regions (Figure 2b).
Phantom position was calibrated using laser guides
in the treatment room. To expose dosemeters to suffi-
cient dose outside the beam field, the phantom was
exposed to the X-ray beam for 30 min in each direc-
tion. The readout values of the glass dosemeters
inside and outside the beam field were converted to
M. NAKAO ETAL.
Page 2 of 9







the absorbed doses for air with the respective calibra-
tion factors. The readout values of the dosemeters on
the surface of the phantom were converted with the
surface calibration factor, and the skin doses were
estimated based on the absorbed doses measured at
six positions (Figure 2c and d).
Organ dose calculation methods
The absorbed doses to an organ dorgan were calculated
using the following equation:




where dair,dry is the absorbed dose in dry air and
[(men/r)organ/(men/r)air, dry] is the ratio of the mass
energy absorption coefficient of an organ to that of dry
air(17). Most organ doses were the average of doses
delivered to all dosemeters for that organ. Due to the
difficulty in selecting appropriate measurement points,
however, organ doses for the bone marrow, bone
surface, colon and skin were estimated by an organ-
specific method. The bone marrow dose (dbone marrow)
and bone surface dose (dbone surface) were estimated
using the dosemeters inserted in bone. For bone
marrow and bone surface, the conversions for absorbed


















where dabs,i is the absorbed dose to soft tissue, which
was converted by Equation (1); Ai is the ratio of each
Figure 1. Arrangement for calibration of glass dosemeters. (a) Arrangement for the calibration factor on surface of
phantom. (b) Arrangement for the calibration factors in phantom and outside beam field.
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fraction to total red bone marrow weight; Mi is the
ratio of each fraction to total mineralised bone weight
and (men/r)cortical tissue and (men/r)soft tissue are the
mass energy absorption coefficients for cortical
bone and soft tissue, respectively. Ai and Mi can be
obtained from ICRP Publication 70(19). The absolute
colon dose (dcolon) was estimated by the following
equations(20):
dcolon ¼ 0:57dULI þ 0:43dLLI; ð4Þ
where dULI and dLLI are the absorbed doses of upper
large intestine and lower large intestine, respectively.
The absorbed skin dose (dskin) was estimated using
the following equations:
dskin ¼ ðdbeamentrance skin þ dbeamexit skinÞ2
 ðAbeamentrance skin þ Abeamexit skinÞ
Atotal skin
; ð5Þ
where (dbeam-entrance skin) and (Abeam-entrance skin) are
the absorbed dose and area at the surface of X-ray
beam entrance, respectively. (dbeam-exit skin) and
(Abeam-exit skin) are the absorbed dose and area at the
exit of the beam through the phantom, respectively.
(Atotal skin) is the total skin surface area of the
phantom(21).
The effective dose was defined as the total of the
tissue-weighted equivalent doses for all tissues and
organs. The effective doses were calculated by
multiplying each organ dose by the tissue weighting
factors suggested by ICRP Publication 103(15).
Exposure conditions for thoracic treatment
To estimate exposure conditions for thoracic treat-
ment, a series of radiographs of an anthropomorphic
chest phantom (Chest Phantom N-1 LUNGMAN;
Kyoto Kagaku Co., Kyoto, Japan) was taken with the
fluoroscopic system by changing tube currents, e.g.
10, 20 and 40 mA, while holding tube voltage, expos-
ure time and pulse rate (image acquisition per second)
constant. The DFPD images were acquired with a
pixel size of 388 mm and a matrix size of 768` 768.
The DFPD image data were imported into Image
J(22) in order to view the DFPD images.
RESULTS
X-ray effective energies and quality indexes
of fluoroscopic system
X-ray effective energies for 60, 80, 100 and 120 kV
were obtained as 33, 36, 39 and 41 keV, and quality
indexes for 60, 80, 100 and 120 kV were obtained as
0.54, 0.45, 0.39 and 0.34, respectively.
Calibration factors of glass dosemeters
The coefficient of variation was defined as the stand-
ard deviation divided by the averaged values. The
maximum coefficient of variation in five calibration
factors was 7.1 % (Table 1). When the organ doses
Figure 2. (a) X-ray fluoroscopic system consisting of a pair of DFPDs and two X-ray tubes. An anthropomorphic phantom
was placed on the treatment couch for dose measurement. (b) Exposure areas were set for the thoracic or abdominal regions.
(c) Measurement points of skin dose for the thoracic treatment. (d) Measurement points of skin dose for the abdominal
treatment.
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were estimated in one measurement, the measured
value contained the variation listed in Table 1.
Measurement of organ doses and effective doses
The results of organ and effective dose measurement
in the thoracic region are listed in Table 2. Values
were normalised to 100 mAs. Standard deviations do
not show measurements reproducibly, but rather the
variation in dose by dosemeters set at particular
points in each organ. The organ doses from both
irradiation directions were 0.96 mGy/100 mAs, 0.88
mGy/100 mAs, 0.48 mGy/100 mAs and 0.41 mGy/
100 mAs for oesophagus, lung, bone surface and
heart. Although breasts are in the thoracic region, the
organ dose was low (0.05 mGy/100 mAs) because the
X-ray entered from the back of the phantom. High
organ doses for bone surface and bone marrow were
due to the direct irradiation of the thoracic vertebrae,
scapulae and ribs. The effective dose for thoracic
treatment was 0.22 mSv/100 mAs.
Table 1. Calibration factors and coefficient of variation.






With Sn filter On surface of phantom 10 1.03`  1023 5.9
In phantom 10 1.09`  1023 4.6
Outside beam field 10 1.2`  1023 3.5
Without Sn filter In phantom 20 2.96`  1024 4.8
Outside beam field 20 3.0`  1024 7.1
Table 2. Organ and effective doses for thoracic treatment.
Thoracic treatment
Projection RPO LPO RPO þ LPO









Brain 0.01 ,0.01 0.01 ,0.01 0.01 0.01
Lens ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
Thyroid 0.09 0.01 0.09 0.02 0.19 0.03
Lung 0.42 0.22 0.46 0.23 0.88 0.43
Oesophagus 0.43 0.26 0.53 0.38 0.96 0.64
Breast 0.03 0.01 0.03 0.01 0.05 0.01
Heart 0.18 0.08 0.23 0.11 0.41 0.16
Liver 0.04 0.02 0.03 0.01 0.07 0.04
Stomach 0.02 0.01 0.03 0.01 0.05 0.02






Ovaries ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
Bladder ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
Testes ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
Bone surface 0.25 0.23 0.48
Bone marrow 0.12 0.10 0.22
Skin 0.04 0.05 0.09
Remainder (male) 0.05 0.06 0.11
Remainder (female) 0.05 0.05 0.10
Effective dose (mSv/100 mAs)
ICRP 103 publication 0.10 0.11 0.22
RPO, right posterior oblique position; LPO, left posterior oblique position; ULI, upper large intestine; LLI, lower large
intestine; SD, standard deviation of readout values in an organ.
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The organ and effective doses in the abdominal
region are listed in Table 3. Large organ doses from
both irradiation directions were 0.61 mGy/100 mAs,
0.59 mGy/100 mAs, 0.39 mGy/100 mAs, 0.36 mGy/
100 mAs and 0.35 mGy/100 mAs for liver, oesopha-
gus, colon, heart and remainder (male), respectively.
The standard deviation for oesophagus dose was
higher than the mean value because the dose distribu-
tion was heterogeneous near the radiation field edge.
Many of the remainder organs were abdominal organs
(spleen/pancreas/adrenal gland/kidney/small intes-
tine), and thus the remainder dose for the abdominal
region was higher than that for the thoracic region.
The effective dose for abdominal treatment was 0.25
mSv/100 mAs.
Skin doses in thoracic and abdominal treatment are
listed in Table 4. The skin dose at the exit of the beam
through the phantom was 3 % of that at the beam
entrance. The maximum skin doses for thoracic and
abdominal treatment were 2.74 mGy/100 mAs and
2.58 mGy/100 mAs, respectively. The maximal dose
point on the skin surface was dependent on the
incident X-ray direction. The maximal dose point
from the bilateral X-ray beams was located between
the right posterior and the left posterior. The
maximum skin dose was at the posterior point
because the posterior point was directly exposed to
both X-ray beams. The effective dose for abdominal
treatment (0.25 mSv/100 mAs) was slightly higher
than that for thoracic treatment (0.22 mSv/100 mAs).
The difference in effective doses between right poster-
ior oblique (RPO) and left posterior oblique (LPO)
was ,10 %. Therefore, effective dose was little
affected by rotation in the plane of the long axis.
Chest phantom images
Three images acquired under different exposure con-
ditions are shown in Figure 3. The region in dashed
circle is around the isocentre in the treatment room.
Image noise generally increases with decreasing dose.
The pulmonary blood vessels in the lung field could
be observed at low exposure dose, whereas those
Table 3. Organ and effective doses for abdominal treatment.
Abdominal treatment
Projection RPO LPO RPO þ LPO









Brain ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 0.01
Lens ,0.01 ,0.01 ,0.01 ,0.01 ,0.01 ,0.01
Thyroid 0.01 ,0.01 0.01 0.01 0.01 0.02
Lung 0.16 0.14 0.16 0.14 0.32 0.24
Oesophagus 0.28 0.47 0.31 0.54 0.59 0.85
Breast 0.03 0.01 0.02 0.01 0.05 0.01
Heart 0.17 0.08 0.19 0.10 0.36 0.10
Liver 0.34 0.18 0.27 0.15 0.61 0.18
Stomach 0.13 0.02 0.17 0.05 0.30 0.02






Ovaries 0.01 ,0.01 0.01 ,0.01 0.01 ,0.01
Bladder ,0.01 ,0.01 ,0.01 ,0.01 0.01 ,0.01
Testes 0.01 ,0.01 ,0.01 ,0.01 0.01 ,0.01
Bone surface 0.16 0.16 0.31
Bone marrow 0.09 0.09 0.19
Skin 0.05 0.04 0.08
Remainder (male) 0.16 0.19 0.35
Remainder (female) 0.15 0.17 0.32
Effective dose (mSv/100 mAs)
ICRP 103 publication 0.12 0.13 0.25
RPO, right posterior oblique position; LPO, left posterior oblique position; ULI, upper large intestine; LLI, lower large
intestine; SD, standard deviation of readout values in an organ.
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obscured by the mediastinum could not be identified
at the lower exposure dose.
DISCUSSION
Thermoluminescent dosemeter has been used for
measurements of organ dose and effective dose(11, 12).
Glass dosemeters have better reproducibility, less
fading effect than the thermoluminescent dose-
meter(23). Although glass dosemeters are not read out
in real-time like silicon pin photodiode(18, 21), the
exposure doses were measured in several hundred
positions at one time. Because the response of the
glass dosemeter depends on X-ray energy in diagnosis
region, effective energy and quality index used for
comparative calibration were equalised to those of
X-ray tubes in treatment room. The glass dosemeters
for the calibrations were selected at random from hun-
dreds of glass dosemeters for actual measurement in
the treatment room because these hundreds of glass
dosemeters have the same lot number in which the
manufacture of grass dosemeter assured that the coef-
ficient of variation was ,1 % in test report. The coef-
ficients of variation in Table 1 were given as overall
Table 4. Skin dose for thoracic and abdominal treatment.
Thoracic treatment Abdominal treatment
Projection RPO LPO RPO þ LPO RPO LPO RPO þ LPO
X-ray tube X-ray tube 1 X-ray tube 2 X-ray tube 1 þ
X-ray tube 2
X-ray tube 1 X-ray tube 2 X-ray tube 1 þ
X-ray tube 2
Skin dose (mGy/100 mAs)
Anterior 0.06 0.07 0.14 0.03 0.03 0.05
Left anterior 0.05 0.05 0.10 0.02 0.05 0.07
Left posterior 0.22 1.53 1.76 0.44 1.31 1.75
Posterior 1.33 1.41 2.74 1.29 1.29 2.58
Right posterior 1.47 0.25 1.71 1.56 0.47 2.03
Right anterior 0.06 0.05 0.12 0.05 0.03 0.07
RPO, right posterior oblique position; LPO, left posterior oblique position.
Figure 3. Images acquired with different tube currents at constant voltage, exposure time, and pulse rate. Upper and lower
panels show RPO and LPO projections, respectively. The region in dashed circle is around the isocentre in treatment room.
(a) 80 kV, 10 mA, 4 ms and 15fps. (b) 80 kV, 20 mA, 4 ms and 15fps. (c) 80 kV, 40 mA, 4 ms and 15fps.
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variation, which consisted of X-ray beam intensity
variation, the glass dosemeter sensitivity variation,
readout error and geometrical setup error.
Organ doses were estimated by averaging the
readout values of glass dosemeters because the posi-
tions of glass dosemeters had been determined in
order to measure a mean organ dose. The minimal
dose 0.01 mGy/100 mAs in Tables 2–4 corresponded
approximately to 0.5 mGy of raw data. Manninen
et al.(24) reported that glass dosemeter had linearity
over 0.02 mGy. Therefore, the dose was sufficient for
obtaining linearity of glass dosemeter, and the dose
distributions in Tables 2–4 have reliable accuracy. The
variations between readout values of glass dosemeters
in an organ were compared qualitatively with standard
deviation in Tables 2 and 3. The variation among
measurement points in the organ (Tables 2 and 3) was
higher than the variation of calibration factor obtained
by a number of measurements (Table 1). Because the
variation of calibration factor was several per cent, the
organ dose level could be estimated with glass dose-
meters. This study quantified organ doses, effective
doses and skin doses for image guidance in carbon-ion
radiotherapy. The beam angle is often fixed in the
treatment room in carbon-ion radiotherapy centre.
Patients are treated at specific beam angles in specific
body postures to keep organs at risk out of the beam.
When patients are treated in such body postures, the
maximal skin dose can decrease. Therefore the actual
maximal skin dose in specific body postures could be
safely estimated by the summed measured maximal
skin dose (number of beams times the maximal skin
dose per one beam).
The irradiation time is over 3–5 min. The treat-
ment time varies in the width of the gating window
and the patient’s respiratory cycle(25). When the
authors assume image acquisition conditions of 80
kV, 20 mA, 4 ms and 15 fps for thoracic regions, the
effective dose and maximal skin dose are 0.48–0.79
mSv per beam angle (¼2.2`  10– 3 mSv mAs21`  72
mAs min21 ` 3–5 min) and 5.9–9.9 mGy per
beam angle (¼2.74` 1022 mGy mAs21` 72 mAs
min21 ` 3–5 min), respectively. The Marburger
Ionen Therapie (MIT) and Heidelberg Ion-Beam
Therapy Center (HIT) have also installed fluoroscopic
systems in their treatment rooms(13). Maximal skin
doses at MIT and HIT when fluoroscopy is performed
for lung cancer treatment are 8 mGy (3 min anterior–
posterior procedure) and 5 mGy (3 min anterior–pos-
terior plus a 3-min left-right procedure), respectively.
The maximal skin doses of the fluoroscopic system
were equal to those of MIT and HIT. In single frac-
tion treatment for lung cancer(26), the beam is deliv-
ered to the target from four beam directions with
vertical or horizontal beams in two oblique positions.
The total effective dose for lung treatment was 1.9–
3.2 mSv (¼0.48–0.79 mSv/beam angle` 4 beams).
The maximal skin dose for lung treatment was 23.6–
39.6 mGy (¼5.9–9.9 mGy/beam angle` 4 beams).
Fujii et al.(18) reported that effective dose of multide-
tector-row CT examination was 8.4–10.9 mSv on
chest examination. Mori et al.(11) reported that effect-
ive doses from helical CT scan mode and from 4DCT
scan mode were 6.09 and 24.7 mSv in thoracic regions
for treatment planning, respectively. Matsuzaki
et al.(12) reported that effective dose of helical
4DCT was 33.1 mSv in thoracic regions for treatment
planning. For lung treatment, the total effective doses
from fluoroscopy were lower than CT in thoracic
regions for treatment planning. However the total
effective dose from fluoroscopy depends on specific
treatment protocol. Because the prescribed dose
range in single fraction treatment from the fluoros-
copy was from 36.0 to 46.0 GyE(27), the maximal skin
dose for lung treatment was 1000 times lower than
the dose from the carbon-ion beam itself. Even if the
planned dose is already very close to the tolerance
dose, an additional dose from fluoroscopy would
rarely trigger the deterministic effect.
The authors estimated the fluoroscopic imaging
dose using an adult anthropomorphic phantom with a
lung cancer treatment protocol. The optimised expos-
ure dose for a markerless tracking system equals the
minimal exposure dose which can track the anatomical
structures, e.g. tumour and pulmonary blood vessels.
The visibility of anatomic structures, e.g. tumour and
pulmonary blood vessels, is a key factor in the accuracy
of markerless tumour tracking in the thorax. The ex-
posure condition was set not by an image quality
index, namely image resolution and signal-to-noise
ratio, but by the visibilities of the figure and outline of
pulmonary blood vessels in the region around the iso-
centre in the images (Figure 3). The exposure condition
for thoracic region was set based on fluoroscopic images
of anthropomorphic phantom. On the other hand, that
for abdominal region was not set by using anthropo-
morphic phantom because anatomical structures were
not visible. Therefore, the tube voltage of X-ray beam
for abdominal region was determined according to the
condition for patient setup. The individual imaging
dose is actually dependent on the treatment protocol
(e.g. gating window and number of fractions) and
patient characteristics (e.g. respiratory pattern and body
type); nevertheless, these results are useful in estimating
the imaging dose from exposure conditions.
CONCLUSION
The present results could show the radiation dose
level in image-guided respiration-gated radiotherapy
by estimating organ dose and effective dose. The
fluoroscopic imaging dose was compared with thera-
peutic beam for a gated strategy in carbon-ion radio-
therapy according to treatment protocol. These
results would be helpful to optimise the imaging dose
in image-guided radiotherapy.
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